Biologic properties and clinical uses of rifaximin (Q37827877)

23 August 2017

1 reference

title

Biologic properties and clinical uses of rifaximin (English)

1 reference

23 August 2017

1

Herbert L DuPont

1 reference

PubMed ID

21226639

23 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

12

1 reference

23 August 2017

293-302

1 reference

23 August 2017

2

1 reference

In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin is a gut-specific human pregnane X receptor activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Systemic pharmacokinetics of rifaximin in volunteers with shigellosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Bile acids improve the antimicrobial effect of rifaximin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Expert review of the evidence base for self-therapy of travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin treatment in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Small intestinal bacterial overgrowth recurrence after antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Methane production during lactulose breath test is associated with gastrointestinal disease presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Mechanisms of hypersensitivity in IBS and functional disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Serotonin, inflammation, and IBS: fitting the jigsaw together?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Interaction between rifaximin and dietary fibre in patients with diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Expert review of the evidence base for prevention of travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Therapy of travelers' diarrhea with rifaximin on various continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin treatment of pathogen-negative travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Management of inflammatory bowel disease: does rifaximin offer any promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Use and safety of rifaximin in children with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

Specificities of the fecal microbiota in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.546347

10.1517/14656566.2011.546347

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21226639